Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

被引：7
作者：
Teng, Gim Gee [1 ,2 ]
Tan-Koi, Wei-Chuen [3 ]
Dong, Di [4 ]
Sung, Cynthia [3 ,5 ]
机构：
[1] Natl Univ Hlth Syst, Univ Med Cluster, Div Rheumatol, Singapore 119228, Singapore
[2] Natl Univ Hlth Syst, Alexandra Hosp, Chron Program, Singapore 159964, Singapore
[3] Hlth Sci Author, Vigilance & Compliance Branch, Singapore 138667, Singapore
[4] Duke Kunshan Univ, Global Hlth Res Ctr, Suzhou 215316, Peoples R China
[5] Duke NUS Med Sch, Hlth Serv & Syst Res, Singapore 169857, Singapore
来源：
PHARMACOGENOMICS | 2020年 / 21卷 / 04期
关键词：
chronic kidney disease; cost-effectiveness; gout; HLA-B*5801 genotyping; Stevens-Johnson syndrome; toxic epidermal necrolysis; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URATE-LOWERING THERAPY; SERUM URATE; STARTING ALLOPURINOL; RENAL-INSUFFICIENCY; NEW-ZEALAND; RISK; COMPLICATIONS; MANAGEMENT;
D O I：
10.2217/pgs-2019-0160
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: Concerns for fatal severe cutaneous adverse reactions (SCARs) hamper allopurinol use. Methods and material: We adopted a health system perspective to evaluate the cost-effectiveness of HLA-B*58:01 genotyping before allopurinol initiation. A decision tree compared three treatment strategies in gout patients with chronic kidney disease who have higher risk for SCAR. They were standard allopurinol treatment followed by febuxostat in nonresponders, test-positive patients receive febuxostat while test-negative receive allopurinol and universal use of febuxostat. Results: The first strategy was the most cost effective. Genotyping dominated universal febuxostat use. Time horizon and SCAR incidence were the most influential factors on the incremental cost-effectiveness ratio. Conclusion: HLA-B*58:01 genotyping compared with standard allopurinol-febuxostat sequential treatment does not provide good value for money in gout with chronic kidney disease.
引用
收藏
页码：279 / 291
页数：13
相关论文
共 60 条
  • [31] 2012 American guidelines for the management of gout as seen by general practitioners. Comment on "GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations." by Goossens et al
    Mourgues, Cindy
    Pereira, Bruno
    Vorilhon, Philippe
    Soubrier, Martin
    Mathieu, Sylvain
    [J]. JOINT BONE SPINE, 2019, 86 (02) : 277 - 278
  • [32] Impact of the HLA-B*58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions
    Ng, Chau Yee
    Yeh, Yu-Ting
    Wang, Chuang-Wei
    Hung, Shuen-Iu
    Yang, Chih-Hsun
    Chang, Ya-Ching
    Chang, Wan-Chun
    Lin, Yu-Jr
    Chang, Chee-Jen
    Su, Shih-Chi
    Fan, Wen-Lang
    Chen, Der-Yuan
    Wu, Yeong-Jian Jan
    Tian, Ya-Chung
    Hui, Rosaline Chung-Yee
    Chung, Wen-Hung
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (07) : 1373 - 1381
  • [33] Physician Adherence to ACR Gout Treatment Guidelines: Perception Versus Practice
    Oderda, Gary. M.
    Shiozawa, Aki
    Walsh, Michael
    Hess, Kyle
    Brixner, Diana I.
    Feehan, Michael
    Akhras, Kasem
    [J]. POSTGRADUATE MEDICINE, 2014, 126 (03) : 257 - 267
  • [34] Long-term follow-up of patients treated for toxic epidermal Necrolysis
    Oplatek, A
    Brown, K
    Sen, S
    Halerz, M
    Supple, K
    Gamelli, RL
    [J]. JOURNAL OF BURN CARE & RESEARCH, 2006, 27 (01) : 26 - 33
  • [35] Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea
    Park, Dong-Jin
    Kang, Ji-Hyoun
    Lee, Jeong-Won
    Lee, Kyung-Eun
    Wen, Lihui
    Kim, Tae-Jong
    Park, Yong-Wook
    Park, Sung-Hwan
    Lee, Shin-Seok
    [J]. ARTHRITIS CARE & RESEARCH, 2015, 67 (02) : 280 - 287
  • [36] The impact of adoption of a new uratelowering agent on trends in utilization and cost in practice
    Peng, Yueh-Lung
    Lee, Chien-Te
    Tain, You-Lin
    Huang, Yaw-Bin
    Chuang, Hung-Yi
    Wen, Yen-Hsia
    Huang, Shiou-Huei
    Tsai, Chun-Yu
    Hsu, Chien-Ning
    [J]. PLOS ONE, 2019, 14 (08):
  • [37] Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations
    Pillai, Nisha Esakimuthu
    Okada, Yukinori
    Saw, Woei-Yuh
    Ong, Rick Twee-Hee
    Wang, Xu
    Tantoso, Erwin
    Xu, Wenting
    Peterson, Trevor A.
    Bielawny, Thomas
    Ali, Mohammad
    Tay, Koon-Yong
    Poh, Wan-Ting
    Tan, Linda Wei-Lin
    Koo, Seok-Hwee
    Lim, Wei-Yen
    Soong, Richie
    Wenk, Markus
    Raychaudhuri, Soumya
    Little, Peter
    Plummer, Francis A.
    Lee, Edmund J. D.
    Chia, Kee-Seng
    Luo, Ma
    De Bakker, Paul I. W.
    Teo, Yik-Ying
    [J]. HUMAN MOLECULAR GENETICS, 2014, 23 (16) : 4443 - 4451
  • [38] Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
    Plumpton, Catrin O.
    Alfirevic, Ana
    Pirmohamed, Munir
    Hughes, Dyfrig A.
    [J]. RHEUMATOLOGY, 2017, 56 (10) : 1729 - 1739
  • [39] Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population
    Pui, Karen
    Gow, Peter J.
    Dalbeth, Nicola
    [J]. JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 872 - 876
  • [40] Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950-2012
    Ramasamy, Sheena N.
    Korb-Wells, Cameron S.
    Kannangara, Diluk R. W.
    Smith, Myles W. H.
    Wang, Nan
    Roberts, Darren M.
    Graham, Garry G.
    Williams, Kenneth M.
    Day, Richard O.
    [J]. DRUG SAFETY, 2013, 36 (10) : 953 - 980
123456